The Role of Lipoprotein (a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post Hoc Analysis of ACCELERATE
- 5 December 2019
- journal article
- letter
- Published by American Diabetes Association in Diabetes Care
- Vol. 43 (2), e22-e24
- https://doi.org/10.2337/dc19-1117
Abstract
No abstract availableFunding Information
- Eli Lilly and Company
This publication has 5 references indexed in Scilit:
- Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular RiskCirculation, 2019
- Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trialsThe Lancet, 2018
- Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular DiseaseThe New England Journal of Medicine, 2017
- A Test in Context: Lipoprotein(a)Journal of the American College of Cardiology, 2017
- Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trialsThe Lancet, 2016